Gesellschaftsrecht / M&A

Immobilien

Steuern

Finanzierungen und Anlageprodukte

Arbeitsrecht und Vergütung für Führungskräfte

IP / IT

Healthcare / Life Sciences

Wettbewerb

Regulierung

Novartis

Homburger News

Homburger and Novartis

On August 22, 2023, Novartis (SIX: NOVN) announced that it had agreed to transfer its real estate and certain infrastructure-related assets and services pertaining to the Life Science Park Rhine Valley in Stein, Canton of Aargau, Switzerland, to the industrial park operator Getec. Currently, almost 2,000 employees work in pharmaceutical and biotechnology companies on the Life Science Park Rhine Valley.
Upon completion of the transaction, the management and further development of the life science park will be taken over by Getec. The transfer is expected to be completed by the end of 2023 and 25 employees will move from Novartis to Getec.
Homburger advises Novartis alongside Freshfields Bruckhaus Deringer on the Swiss law and tax aspects of the transaction. The Homburger team is led by Daniel Häusermann (Corporate / M&amp;A, Real Estate) and includes Olivier Bühlmann, Daniel Kuhn (both Corporate / M&amp;A, Real Estate), Stefan Gäumann (Real Estate), Oriana Schöni (Corporate / M&amp;A), Reto Heuberger, Peter Müller and Philippe Weber (all Tax), Jürg Frick (Financing and Investment Products), Gregor Bühler and Marc Bircher (both Employment), Andri Hess (IP / IT, Healthcare / Life Sciences), Allegra Arnold and Katharina Bratvogel (both Competition, Regulatory), as well as other professionals.

Homburger advises Novartis on the transfer of the Life Science Park Rhine Valley to Getec

On December 13, 2022, Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that it has entered into a definitive agreement to acquire AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump, an insulin delivery solution.
The consideration includes a previous strategic investment of CHF 8.0 m, an upfront cash payment of CHF 62.4 m, and additional contingent earnout payments of up to CHF 129.6 m, in aggregate, payable upon the achievement of certain milestones. The transaction is subject to the satisfaction of customary closing conditions and is expected to close in January 2023.
Homburger, who also advised AMF Medical on its previous financing rounds, acts as transaction counsel to AMF Medical SA and its shareholders. The Homburger team comprises Andreas Müller, Margrit Marti and Léonard Aeschlimann Perales (all Corporate / M&amp;A; Healthcare / Life Sciences), Luca Dal Molin and Joel Fink (both IP / IT; Healthcare / Life Sciences), Stefan Oesterhelt, Kevin Müller and Philippe Weber (all Tax), Richard Stäuber and Allegra Arnold (both Competition; Healthcare / Life Sciences), and Marc Bircher and Sebastian Wyler (both Employment and Executive Compensation).

Homburger advises AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

Kapitalmarkt

Credit Suisse

On October 27, 2022, Credit Suisse Group AG announced that its Board of Directors will propose to an Extraordinary General Meeting to be held on November 23, 2022, to approve two separate share capital increases: a first capital increase of an expected CHF 1.76 bn through the issuing of new shares to a number of qualified investors, including Saudi National Bank, where preemptive subscription rights of existing shareholders are excluded, and a second capital increase of approximately CHF 2.24 bn through a rights offering to existing shareholders. The shares to be issued in the rights offering are underwritten, subject to customary conditions, by a syndicate of banks in the amount of up to CHF 4 bn should the first capital increase not be fully implemented, e.g. if the shareholders of Credit Suisse Group AG approve the rights offering but not the first capital increase with exclusion of preemptive rights. Through the proposed share capital increases, Credit Suisse Group AG intends to raise CHF 4.0 bn to further strengthen the Group’s capital base and support its strategic transformation.
Homburger advises Credit Suisse Group AG in the structuring of the capital increase, on the transaction documentation, and on all Swiss law regulatory, tax and transactional aspects of the issuance, offering and listing of the new shares.
The Homburger team was led by partner Benjamin Leisinger (Capital Markets) and included partners Claude Lambert, Daniel Daeniker and Andreas Müller (all Corporate / M&amp;A), partner Dieter Grünblatt (Tax), lead associate Daniel Hulmann, counsel Lee Saladino and associate Sofiya Shavlak (all Capital Markets), associates Margrit Marti, Claudine Schär, Romain Fakhoury (all Corporate / M&amp;A) and Marc Bircher (Employment and Executive Compensation) as well as junior associate Lars Schöni (Capital Markets).

Homburger advises Credit Suisse Group AG in connection with the share capital increases of CHF 4 bn to further strengthen the Group’s capital base and support its new strategic direction

Marc
Bircher

Homburger advises Novartis on the transfer of the Life Science Park Rhine Valley to Getec

Homburger advises AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

Homburger advises Credit Suisse Group AG in connection with the share capital increases of CHF 4 bn to further strengthen the Group’s capital base and support its new strategic direction

Chapter 9: Employment Contracts

Join the Team

Marc Bircher

Karriere

Sprachen

Zulassung

Teams

MarcBircher

Homburger advises Novartis on the transfer of the Life Science Park Rhine Valley to Getec

Homburger advises AMF Medical and its shareholders on the sale of AMF Medical to Tandem Diabetes Care

Homburger advises Credit Suisse Group AG in connection with the share capital increases of CHF 4 bn to further strengthen the Group’s capital base and support its new strategic direction

Chapter 9: Employment Contracts

Join the Team

Marc Bircher

Karriere

Sprachen

Zulassung

Teams

Marc
Bircher